-
1دورية أكاديمية
المؤلفون: Goodman OB Jr.
المصدر: Oncology (08909091); Jun2009, Vol. 23 Issue 7, p632-635, 2p
-
2دورية أكاديمية
المؤلفون: Goodman OB Jr., Dang NH
المصدر: Clinical Lymphoma & Myeloma; Dec2008 Supplement 5, Vol. 8, pS193-8, 1p
-
3دورية أكاديمية
المؤلفون: Msaouel P; University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: PMsaouel@mdanderson.org., Sweis RF; University of Chicago Medicine, Chicago, IL, USA., Bupathi M; Rocky Mountain Cancer Centers - Littleton, Littleton, CO, USA., Heath E; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA., Goodman OB Jr; Comprehensive Cancer Centers of Nevada - Southwest, Las Vegas, NV, USA., Hoimes CJ; Duke University Hospital, Durham, NC, USA., Milowsky MI; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Davis N; Vanderbilt - Ingram Cancer Center, Nashville, TN, USA., Kalebasty AR; University of California Irvine, Irvine, CA, USA., Picus J; Washington University School of Medicine, Siteman Cancer Center, Saint Louis, MO, USA., Shaffer D; New York Oncology Hematology - Albany Medical Center, Albany, NY, USA., Mao S; Allegheny General Hospital, Pittsburgh, PA, USA., Adra N; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA., Yorio J; Texas Oncology - Austin Central, Austin, TX, USA., Gandhi S; Florida Cancer Specialists and Research Institute - North Region (SCRI), Tampa Bay, FL, USA., Grivas P; Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA., Siefker-Radtke A; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang R; Mirati Therapeutics, Inc., San Diego, CA, USA., Latven L; Mirati Therapeutics, Inc., San Diego, CA, USA., Olson P; Mirati Therapeutics, Inc., San Diego, CA, USA., Chin CD; Mirati Therapeutics, Inc., San Diego, CA, USA., Der-Torossian H; Mirati Therapeutics, Inc., San Diego, CA, USA., Mortazavi A; Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, and the Comprehensive Cancer Center, Columbus, OH, USA., Iyer G; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
المصدر: European urology oncology [Eur Urol Oncol] 2024 Aug; Vol. 7 (4), pp. 933-943. Date of Electronic Publication: 2023 Dec 16.
نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE
مواضيع طبية MeSH: Nivolumab*/therapeutic use , Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/secondary , Carcinoma, Transitional Cell*/pathology , Carcinoma, Transitional Cell*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Aged ; Male ; Female ; Middle Aged ; Aged, 80 and over ; Adult ; Neoplasm Metastasis ; Urologic Neoplasms/drug therapy ; Urologic Neoplasms/pathology ; Urologic Neoplasms/mortality ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/pathology
-
4دورية أكاديمية
المؤلفون: Saad F; Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, QC, Canada. Electronic address: fred.saad@umontreal.ca., Efstathiou E; Athens Medical Center, Dept of GU Oncology, Athens, Greece., Attard G; University College London, London, UK., Flaig TW; University of Colorado Cancer Center, Aurora, CO, USA., Franke F; ONCOSITE, Hospital Unimed Noroeste, Ijuí, Brazil., Goodman OB Jr; Comprehensive Cancer Centers of Nevada, US Oncology Network, Las Vegas, NV, USA., Oudard S; Georges Pompidou Hospital, University of Paris, Paris, France., Steuber T; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Suzuki H; Toho University Sakura Medical Center, Chiba, Japan., Wu D; Janssen Research & Development, Los Angeles, CA, USA., Yeruva K; Janssen Research & Development, Los Angeles, CA, USA., De Porre P; Janssen Research & Development, Beerse, Belgium., Brookman-May S; Janssen Research & Development, Los Angeles, CA, USA; Ludwig Maximilians University, Munich, Germany., Li S; Janssen Research & Development, Spring House, PA, USA., Li J; Janssen Research & Development, San Diego, CA, USA., Thomas S; Janssen Research & Development, Spring House, PA, USA., Bevans KB; Janssen Global Services, Horsham, PA, USA., Mundle SD; Janssen Research & Development, Raritan, NJ, USA., McCarthy SA; Janssen Research & Development, Raritan, NJ, USA., Rathkopf DE; Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY, USA.
مؤلفون مشاركون: ACIS Investigators
المصدر: The Lancet. Oncology [Lancet Oncol] 2021 Nov; Vol. 22 (11), pp. 1541-1559. Date of Electronic Publication: 2021 Sep 30.
نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
مواضيع طبية MeSH: Abiraterone Acetate/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Prednisone/*therapeutic use , Prostatic Neoplasms, Castration-Resistant/*drug therapy , Thiohydantoins/*therapeutic use, Aged ; Androgen Receptor Antagonists/therapeutic use ; Double-Blind Method ; Drug-Related Side Effects and Adverse Reactions/diagnosis ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/therapy ; Humans ; Male ; Neoplasm Metastasis ; Progression-Free Survival ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Steroid Synthesis Inhibitors/therapeutic use ; Survival Rate
-
5دورية أكاديمية
المؤلفون: Chao OS; College of Medicine, Roseman University of Health Sciences, Las Vegas, Nevada, USA., Goodman OB Jr; College of Medicine, Roseman University of Health Sciences, Las Vegas, Nevada, USA.; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA.
المصدر: The Prostate [Prostate] 2021 Oct; Vol. 81 (14), pp. 1032-1048. Date of Electronic Publication: 2021 Jul 23.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8101368 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0045 (Electronic) Linking ISSN: 02704137 NLM ISO Abbreviation: Prostate Subsets: MEDLINE
مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , DNA Damage/*drug effects , DNA-Activated Protein Kinase/*antagonists & inhibitors , Drug Resistance, Neoplasm/*drug effects , Protein Kinase Inhibitors/*pharmacology , Taxoids/*pharmacology, Cell Line, Tumor ; Cell Survival/drug effects ; Chromones/pharmacology ; Docetaxel/pharmacology ; Etoposide/pharmacology ; Humans ; Male ; Morpholines/pharmacology ; Prostatic Neoplasms ; Pyridazines/pharmacology ; Quinazolines/pharmacology
-
6دورية أكاديمية
المؤلفون: Gorjala P; Department of Biomedical Sciences, College of Medicine, Roseman University of Health Sciences, 10530 Discovery Drive, Las Vegas, NV 89135, USA., Kittles RA; Department of population Sciences, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA., Goodman OB Jr; Department of Internal Medicine, College of Medicine, Roseman University of Health Sciences, 10530 Discovery Drive, Las Vegas, NV 89135, USA., Mitra R; Department of Biomedical Sciences, College of Medicine, Roseman University of Health Sciences, 10530 Discovery Drive, Las Vegas, NV 89135, USA.
المصدر: Cancers [Cancers (Basel)] 2020 Apr 17; Vol. 12 (4). Date of Electronic Publication: 2020 Apr 17.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
-
7دورية أكاديمية
المؤلفون: Carducci M; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1M59 Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD, 21287, USA. Carducci@jhmi.edu., Shaheen M; University of Arizona Cancer Center, Tucson, AZ, USA., Markman B; Monash Health, Melbourne, VIC, Australia., Hurvitz S; University of California Los Angeles, Los Angeles, CA, USA., Mahadevan D; University of Arizona Cancer Center, Tucson, AZ, USA., Kotasek D; Adelaide Cancer Centre, Kurralta Park, Adelaide, SA, Australia., Goodman OB Jr; Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA., Rasmussen E; Amgen Inc., Thousand Oaks, CA, USA., Chow V; Amgen Inc., Thousand Oaks, CA, USA., Juan G; Amgen Inc., Thousand Oaks, CA, USA., Friberg GR; Amgen Inc., Thousand Oaks, CA, USA., Gamelin E; Amgen Inc., Thousand Oaks, CA, USA., Vogl FD; Amgen Inc., Thousand Oaks, CA, USA., Desai J; Royal Melbourne Hospital, Parkville, VIC, Australia.
المصدر: Investigational new drugs [Invest New Drugs] 2018 Dec; Vol. 36 (6), pp. 1060-1071. Date of Electronic Publication: 2018 Jul 07.
نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
مواضيع طبية MeSH: Aurora Kinases/*antagonists & inhibitors , Neoplasms/*drug therapy , Neoplasms/*pathology , Phthalazines/*administration & dosage , Phthalazines/*therapeutic use , Protein Kinase Inhibitors/*administration & dosage , Protein Kinase Inhibitors/*therapeutic use, Administration, Oral ; Adult ; Aged ; Aurora Kinases/metabolism ; Biomarkers, Tumor/metabolism ; Cohort Studies ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Staging ; Phthalazines/adverse effects ; Phthalazines/pharmacokinetics ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacokinetics ; Treatment Outcome
-
8دورية أكاديمية
المؤلفون: Mitra R; College of Medicine, Roseman University of Health Sciences, 10530 Discovery drive, Las Vegas, NV, 89135, USA. rmitra@roseman.edu., Le TT; College of Medicine, Roseman University of Health Sciences, 10530 Discovery drive, Las Vegas, NV, 89135, USA., Gorjala P; College of Medicine, Roseman University of Health Sciences, 10530 Discovery drive, Las Vegas, NV, 89135, USA., Goodman OB Jr; College of Medicine, Roseman University of Health Sciences, 10530 Discovery drive, Las Vegas, NV, 89135, USA. ogoodman@roseman.edu.; Comprehensive Cancer Centers of Nevada, 9280 W Sunset Road, Las Vegas, NV, 89148, USA. ogoodman@roseman.edu.
المصدر: BMC cancer [BMC Cancer] 2017 Sep 06; Vol. 17 (1), pp. 631. Date of Electronic Publication: 2017 Sep 06.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
مواضيع طبية MeSH: 1-Acylglycerol-3-Phosphate O-Acyltransferase/*metabolism , Diacylglycerol O-Acyltransferase/*metabolism , Lipid Droplets/*metabolism , Prostatic Neoplasms/*metabolism, 1-Acylglycerol-3-Phosphate O-Acyltransferase/genetics ; Apoptosis/genetics ; Autophagy ; Cell Cycle/genetics ; Cell Line, Tumor ; Diacylglycerol O-Acyltransferase/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Lipid Metabolism ; Male ; Models, Biological ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/pathology ; RNA Interference ; RNA, Small Interfering/genetics ; RNA, Small Interfering/metabolism
-
9دورية أكاديمية
المؤلفون: Mitra R; College of Biomedical Sciences, Roseman University of Health Sciences, Nevada., Goodman OB Jr
المصدر: The Prostate [Prostate] 2015 Apr 01; Vol. 75 (5), pp. 527-38. Date of Electronic Publication: 2015 Jan 13.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8101368 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0045 (Electronic) Linking ISSN: 02704137 NLM ISO Abbreviation: Prostate Subsets: MEDLINE
مواضيع طبية MeSH: Cytochrome P-450 CYP3A/*physiology , Prostatic Neoplasms/*enzymology , Receptors, Androgen/*metabolism , Signal Transduction/*physiology, Blotting, Western ; Bridged-Ring Compounds/pharmacology ; Cell Line, Tumor ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Dihydrotestosterone/pharmacology ; Fluorescent Antibody Technique ; Humans ; Male ; Metribolone/pharmacology ; Prostatic Neoplasms/pathology ; RNA, Small Interfering/pharmacology ; Real-Time Polymerase Chain Reaction ; Triazoles/pharmacology
-
10دورية أكاديمية
المؤلفون: Chao OS; Cancer Research Center, College of Medicine, Roseman University of Health Sciences, Las Vegas, Nevada., Goodman OB Jr; Cancer Research Center, College of Medicine, Roseman University of Health Sciences, Las Vegas, Nevada. Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada. ogoodman@roseman.edu.
المصدر: Molecular cancer research : MCR [Mol Cancer Res] 2014 Dec; Vol. 12 (12), pp. 1755-66. Date of Electronic Publication: 2014 Aug 15.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101150042 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3125 (Electronic) Linking ISSN: 15417786 NLM ISO Abbreviation: Mol Cancer Res Subsets: MEDLINE
مواضيع طبية MeSH: BRCA1 Protein/*metabolism , DNA Repair/*drug effects , Enzyme Inhibitors/*pharmacology , Hydroxamic Acids/*pharmacology , Phthalazines/*pharmacology , Piperazines/*pharmacology , Prostatic Neoplasms/*metabolism, BRCA1 Protein/genetics ; Cell Line, Tumor ; Cell Survival/drug effects ; DNA Breaks, Double-Stranded/drug effects ; Drug Synergism ; Gene Expression Regulation, Neoplastic/drug effects ; Histone Deacetylases/metabolism ; Humans ; Male ; Poly(ADP-ribose) Polymerase Inhibitors ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/pathology ; Rad51 Recombinase/genetics ; Rad51 Recombinase/metabolism ; Vorinostat